Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus
Objective Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficac...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/12/1/e001438.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590855951613952 |
|---|---|
| author | Sung-Hwan Park Seung-Ki Kwok Wan-Uk Kim Ji Hyeon Ju Jiwon Yang Youngjae Park Jennifer Jooha Lee |
| author_facet | Sung-Hwan Park Seung-Ki Kwok Wan-Uk Kim Ji Hyeon Ju Jiwon Yang Youngjae Park Jennifer Jooha Lee |
| author_sort | Sung-Hwan Park |
| collection | DOAJ |
| description | Objective Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.Methods A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included. Changes in the T-score and areal bone mineral density (BMD) at the lumbar spine, total hip and femur neck from denosumab initiation to 12 months were measured. Correlation analysis was performed between the degree of BMD improvement and covariates including SLE-specific factors such as SLE duration, SLE Disease Activity Index 2000 (SLEDAI-2K) score, glucocorticoid dose and hydroxychloroquine use. Multiple linear regression analysis was conducted to identify predictors of the therapeutic efficacy of denosumab.Results Denosumab significantly increased BMD and decreased bone turnover markers at 12 months compared with baseline. The degree of BMD improvement revealed a significant negative correlation with SLEDAI-2K score, hydroxychloroquine use, prior osteoporosis treatment and baseline BMD values. In contrast, body mass index and c-telopeptide of collagen type 1 levels were positively correlated with the degree of BMD improvement. Higher baseline BMD values, SLEDAI-2K scores and hydroxychloroquine use were significant predictors of attenuated BMD improvement.Conclusions Our study suggests that denosumab is an effective treatment option for osteoporosis in patients with SLE. The therapeutic efficacy of denosumab can be predicted by baseline BMD values, SLEDAI-2K scores and hydroxychloroquine use. |
| format | Article |
| id | doaj-art-f526a377cc9d4482ad43f6cbeddb7fe4 |
| institution | Kabale University |
| issn | 2053-8790 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj-art-f526a377cc9d4482ad43f6cbeddb7fe42025-01-23T07:30:09ZengBMJ Publishing GroupLupus Science and Medicine2053-87902025-01-0112110.1136/lupus-2024-001438Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosusSung-Hwan Park0Seung-Ki Kwok1Wan-Uk Kim2Ji Hyeon Ju3Jiwon Yang4Youngjae Park5Jennifer Jooha Lee6Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaObjective Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.Methods A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included. Changes in the T-score and areal bone mineral density (BMD) at the lumbar spine, total hip and femur neck from denosumab initiation to 12 months were measured. Correlation analysis was performed between the degree of BMD improvement and covariates including SLE-specific factors such as SLE duration, SLE Disease Activity Index 2000 (SLEDAI-2K) score, glucocorticoid dose and hydroxychloroquine use. Multiple linear regression analysis was conducted to identify predictors of the therapeutic efficacy of denosumab.Results Denosumab significantly increased BMD and decreased bone turnover markers at 12 months compared with baseline. The degree of BMD improvement revealed a significant negative correlation with SLEDAI-2K score, hydroxychloroquine use, prior osteoporosis treatment and baseline BMD values. In contrast, body mass index and c-telopeptide of collagen type 1 levels were positively correlated with the degree of BMD improvement. Higher baseline BMD values, SLEDAI-2K scores and hydroxychloroquine use were significant predictors of attenuated BMD improvement.Conclusions Our study suggests that denosumab is an effective treatment option for osteoporosis in patients with SLE. The therapeutic efficacy of denosumab can be predicted by baseline BMD values, SLEDAI-2K scores and hydroxychloroquine use.https://lupus.bmj.com/content/12/1/e001438.full |
| spellingShingle | Sung-Hwan Park Seung-Ki Kwok Wan-Uk Kim Ji Hyeon Ju Jiwon Yang Youngjae Park Jennifer Jooha Lee Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus Lupus Science and Medicine |
| title | Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus |
| title_full | Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus |
| title_fullStr | Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus |
| title_full_unstemmed | Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus |
| title_short | Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus |
| title_sort | factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus |
| url | https://lupus.bmj.com/content/12/1/e001438.full |
| work_keys_str_mv | AT sunghwanpark factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus AT seungkikwok factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus AT wanukkim factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus AT jihyeonju factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus AT jiwonyang factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus AT youngjaepark factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus AT jenniferjoohalee factorsinfluencingtherapeuticefficacyofdenosumabagainstosteoporosisinsystemiclupuserythematosus |